A Randomized, Double-Blind, Parallel, Comparative Assessment of the Pharmacokinetics, Safety, and Immunogenicity of Three Preparations of Bevacizumab, Following a Single I.V. Dose of 1 mg/kg in Healthy Male Volunteers
Latest Information Update: 12 Nov 2020
At a glance
- Drugs Bevacizumab (Primary)
- Indications Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer
- Focus Pharmacokinetics
- Sponsors Aurobindo Pharma
Most Recent Events
- 11 Nov 2020 Status changed from not yet recruiting to completed.
- 25 Sep 2019 New trial record